SMMT

OPPORTUNITY IN BIOTECH WITHIN BUYOUT POTENTIAL BEATING GOLD STANDARD IN LUNG CANCER TREATMENT

By Nigam Arora & Dr. Natasha Arora Better Than Gold Standard In a Phase 3 study, Summit Therapeutics Inc’s (SMMT) drug showed a statistically significant 5.3 months of improvement in progression free survival versus Keytruda in treatment of PD-L1- positive advanced non-small cell lung cancer.  Keytruda from MRK is the gold standard.

Read More

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content